Sign up USA
Proactive Investors - Run By Investors For Investors

Marinus Pharmaceuticals shares surge on Nasdaq on successful clinical trial results

The candidate is being used to treat CDKL5 - a rare genetic disorder
Marinus Pharmaceuticals shares surge on Nasdaq on successful clinical trial results
It mainly affects girls and is characterized by early-onset, difficult-to-control seizures and severe neuro developmental impairment

Shares in Marinus Pharmaceuticals (NASDAQ:MRNS) added over 46% on Nasdaq to $4.57 as it posted positive top-line data from a phase 2 study assessing orphan drug-tagged ganaxolone.

The candidate is being used to treat  CDKL5  - a rare genetic disorder, which is caused by a mutation of the cyclin-dependent kinase-like 5 (CDKL5) gene, located on the X chromosome.

It mainly affects girls and is characterized by early-onset, difficult-to-control seizures and severe neuro‑developmental impairment.

Dr Orrin Devinsky, the principal investigator in the current study, said: “I am impressed with the magnitude of seizure reduction and gain in seizure-free days seen with ganaxolone treatment in children with this highly refractory epilepsy.

"The durable anti-epileptic effect seen in several children distinguishes ganaxolone’s efficacy from the more than 20 currently available anti-epileptic drugs that provide limited seizure control lasting a few weeks to months.

"When treating children with the severest forms of epilepsy such as CDKL5 disorder, there is a desperate need for new drugs that are well-tolerated, efficacious and easy to administer with no need for special monitoring.

"With no other treatment showing this degree of promise, I am excited to lead the effort to advance ganaxolone into potentially the first, late-stage clinical trial in children with CDKL5 disorder.”

View full MRNS profile View Profile

Marinus Timeline

Related Articles

Picture of drugs
July 18 2017
Gross profit in the half year to December was up by 34%
Lab technician
August 07 2017
Avacta said it has developed multiple PD-L1 inhibitors, which are designed to use the body's own immune system to battle cancer
picture of drug research
August 22 2017
With US licensee driving the Phase 1 trials of Sareum's lead candidate, SRA737, the focus moves to TYK2, a compound that is targeting psoriasis, rheumatoid arthritis, and other autoimmune disorders
Copyright © Proactiveinvestors.com, 2017. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use